Leerink upgrades CVS Health to Outperform, sees ‘positively skewed’ reward
Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...
Replimune price target raised to $21 from $18 at Leerink
Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...
What is Leerink Partnrs’ Estimate for UTHR FY2024 Earnings?
Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects ...
Investment Banker Cleared to Seek Multi-Million Bonuses Against Former Boston Employer
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
Leerink lifts Inspire Medical stock target to $194, maintains rating
Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...
Leerink Partnrs Has Negative Outlook of VKTX FY2025 Earnings
Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...
Ex-Goldman Banker Advances Some Pay Claims Against Leerink Firm
An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...
CLYM Stock Touches 52-Week Low at $1.5 Amid Market Challenges
In a challenging market environment, shares of Eliem Therapeutics, Inc. (CLYM) have reached a 52-week low, dipping to $1.5. According to InvestingPro data, the company maintains a strong financial ...
Business Insider3y
SVB Leerink has staffed up with at least 18 hires to chase hot tech deals — and adding ECM and fintech bankers is next
Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...
Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...
Nasdaq15d
Leerink Partners Upgrades Doximity (DOCS)
Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...
Nasdaq6d
Leerink Partners Downgrades Hologic (WBAG:HOLX)
Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (WBAG:HOLX) from Outperform to Market Perform. There are 1,442 funds or institutions reporting ...